← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV17행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)
Triumvira Immunologics, Inc.·HER2
1 trials
Overview
Program
TAC01-HER2 plus pembrolizumab
Overview
Company
Triumvira Immunologics, Inc.
Overview
Modality
ANTIBODY
Overview
Target
HER2
Overview
Indication
HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials.. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for metastatic colorectal cancer (mCRC) exhibiting DNA mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). However, the comparative …
Clinical
Safety signal
Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials.. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for metastatic colorectal cancer (mCRC) exhibiting DNA mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). However, the comparative …
Clinical
Reported ORR
0%
Clinical
Result source
ClinicalTrials.gov NCT04727151
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT04727151